Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Spotify Technology — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Spotify Technology trades at $501.85 (market cap $105.22B). The key difference: Spotify Technology is far larger — about 20.8× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| ACAD | SPOT | |
|---|---|---|
Market Cap | $5.06B | $105.22B |
Sector | Health | Media |
52-Week High | $29.41 | $738.53 |
52-Week Low | $20.06 | $412.75 |
Enterprise Value | $4.18B | $94.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Spotify (SPOT) trades at $488.14, up 2.75% with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with Q2 2026 revenue growth of 14% year-over-year and record gross margins of 33.4%, though earnings missed expectations due to increased marketing and AI costs. Premium subscribers surpassed 300 million for the first time, supporting the long-term growth narrative.
Wall Street maintains a bullish outlook with 61.5% buy ratings and a $598.20 consensus price target representing 22.5% upside potential. Key risks include execution on AI investments, competitive pressure in streaming, and margin sustainability. The stock presents growth opportunity if monetization initiatives succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
